Form: 8-K

Current report

November 6, 2025

img125368884_0.jpg

TerrAscend Reports Third Quarter 2025 Financial Results

 

Net Revenue of $65.1 million

 

Gross Profit Margin of 52.1% from continuing operations, up 110 basis points from 51.0% in the third quarter of 2024

 

Net Cash provided from continuing operations of $7.1 million and Free Cash Flow¹ of $4.9 million

13th consecutive quarter of positive Cash Flow from continuing operations and 9th consecutive quarter of positive Free Cash Flow¹

 

During the quarter, completed a $79 million non-dilutive refinancing of existing debt with an additional uncommitted term loan facility of up to $35 million for strategic M&A

 

TORONTO, November 6, 2025 - TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today reported its financial results for the third quarter ended September 30, 2025. All amounts are expressed in U.S. dollars and are prepared under U.S. Generally Accepted Accounting Principles (GAAP), unless indicated otherwise.

 

The following financial measures are reported as results from continuing operations unless otherwise noted, due to the Company’s previously stated intention to sell all of its Michigan assets, which are reported as discontinued operations effective as of the second quarter ended June 30, 2025. All historical periods have been restated accordingly.

 

Third Quarter 2025 Financial Highlights

Net Revenue was $65.1 million, compared to $65.0 million in Q2 2025 and $65.2 million in Q3 2024.
Gross Profit Margin was 52.1%, compared to 51.1% in Q2 2025 and 51.0% in Q3 2024.
GAAP Net Loss from continuing operations was $9.9 million, compared to $6.4 million in Q2 2025 and $15.8 million in Q3 2024.
EBITDA from continuing operations¹ was $14.3 million, compared to $15.9 million in Q2 2025 and $9.7 million in Q3 2024.
Adjusted EBITDA from continuing operations¹ was $17.0 million, compared to $16.0 million in Q2 2025 and $16.9 million in Q3 2024.
Adjusted EBITDA Margin from continuing operations¹ was 26.1%, compared to 24.6% in Q2 2025 and 25.9% in Q3 2024.
Net Cash provided from continuing operations was $7.1 million, after net tax payments of $5 million during the quarter, compared to $7.3 million in Q2 2025 and $6.1 million in Q3 2024.
Free Cash Flow¹ was $4.9 million, compared to $5.0 million in Q2 2025 and $6.1 million in Q3 2024.

 

“I’m pleased to report that both gross margins and Adjusted EBITDA margins improved meaningfully in the third quarter of 2025, marking another quarter of steady progress. This represents our 13th consecutive quarter of positive cash flow from continuing operations and our 9th consecutive quarter of positive free cash flow. Revenue from continuing operations remained stable year-over-year, supported by consistent performance across our key Northeast markets of New Jersey, Maryland, and Pennsylvania. In New Jersey, we maintained our leadership position, according to BDSA, and in Pennsylvania, four of our six stores ranked among the top ten statewide. In Maryland, our success story continues with a 14.8% increase in revenue year-over-year and gross margin in the high 50’s,” said Jason Wild, Executive Chairman of TerrAscend.

 

“Since announcing our decision to exit the Michigan market, we have made significant progress and remain on track to complete these divestitures by year-end. At the same time, we continue to evaluate strategic opportunities through a disciplined M&A approach. Our fundamentals are improving, our balance sheet remains strong with increased cash and no material debt maturities for several years, and we are well-positioned to benefit from potential state and federal regulatory developments,” concluded Mr. Wild.

 


Financial Summary Q3 2025 and Comparative Periods

 

(in millions of U.S. Dollars)

 

Q3 2025

 

 

Q2 2025

 

 

Q3 2024

 

Revenue, net

 

 

65.1

 

 

 

65.0

 

 

 

65.2

 

Quarter-over-Quarter increase

 

 

0.1

%

 

 

 

 

 

 

Year-over-Year decrease

 

 

-0.1

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

33.9

 

 

 

33.2

 

 

 

33.2

 

Gross profit margin

 

 

52.1

%

 

 

51.1

%

 

 

51.0

%

 

 

 

 

 

 

 

 

 

 

General & Administrative expenses

 

 

21.3

 

 

 

21.0

 

 

 

24.7

 

Share-based compensation expense (included in G&A expenses above)

 

 

1.4

 

 

 

0.8

 

 

 

4.3

 

G&A as a % of revenue, net

 

 

32.8

%

 

 

32.3

%

 

 

37.9

%

 

 

 

 

 

 

 

 

 

 

Net loss from continuing operations

 

 

(9.9

)

 

 

(6.4

)

 

 

(15.8

)

 

 

 

 

 

 

 

 

 

 

EBITDA from continuing operations1

 

 

14.3

 

 

 

15.9

 

 

 

9.7

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA from continuing operations1

 

 

17.0

 

 

 

16.0

 

 

 

16.9

 

Adjusted EBITDA Margin from continuing operations1

 

 

26.1

%

 

 

24.6

%

 

 

25.9

%

 

 

 

 

 

 

 

 

 

 

Net cash provided by operations - continuing operations

 

 

7.1

 

 

 

7.3

 

 

 

6.1

 

 

 

 

 

 

 

 

 

 

 

Free Cash Flow1

 

 

4.9

 

 

 

5.0

 

 

 

6.1

 

 

 

Third Quarter 2025 Business and Operational Highlights

During the quarter, completed a $79 million non-dilutive refinancing of existing debt with an additional uncommitted term loan facility of up to $35 million for strategic M&A.
Achieved 13th consecutive quarter of positive cash flow from continuing operations and 9th consecutive quarter of positive free cash flow.
Maintained leadership position in New Jersey2.
Apothecarium store in Phillipsburg is the #1 store in New Jersey out of nearly 250 licensed dispensaries3.
Kind Tree and Legend brands consistently remained in the top 10 brands across New Jersey, even as the number of brands in market has doubled to more than 200 in the past year2.
With the launch of new preroll assortment in New Jersey, category sales increased by 32% and improved share and rank quarter-over-quarter2.
Kind Tree Cherry Slushee is TerrAscend’s bestseller in New Jersey, ranking #8 out of over 3,000 flower products sold in Q32.
In Maryland, the Cumberland and Salisbury Apothecarium locations are top 5 dispensaries in the state3.
Four of six Apothecarium stores rank in the top 10 across the state of Pennsylvania3.
The Board of Directors authorized the Company to renew and replenish its normal course issuer bid to repurchase up to $10 million US dollars of the company’s common shares from time to time over a 12- month period.
Announced decision to exit the Michigan market, with plans to divest substantially all Michigan assets including dispensaries and cultivation/processing facilities by the end of 2025 and use the net proceeds to pay down existing debt.

 

1. EBITDA from continuing operations, Adjusted EBITDA from continuing operations, Adjusted EBITDA margin from continuing operations, and Free Cash Flow are non-GAAP measures defined in the section titled “Definition and Reconciliation of Non-GAAP Measures” below and reconciled to the most directly comparable GAAP measure at the end of this release.

2. Source: BDSA

3. Source: LIT Alerts

 

Third Quarter 2025 Financial Results


Net revenue for the third quarter of 2025 was $65.1 million, compared to $65.0 million for the second quarter of 2025 and $65.2 million for the third quarter of 2024, which was in line with the expectations communicated on last quarter’s earnings conference call. Retail revenue increased 3.4% year-over-year and 0.7% sequentially. Wholesale revenue declined 6.7% year-over-year and 1.1% sequentially.

 

Gross profit margin from continuing operations for the third quarter of 2025 improved to 52.1%, as compared to 51.1% for the second quarter of 2025 and 51.0% for the third quarter of 2024.

 

G&A expenses for the third quarter of 2025 were $21.3 million and 32.8% of revenue, compared to $21.0 million and 32.3% of revenue in the second quarter of 2025 and $24.7 million and 37.9% of revenue in the third quarter of 2024.


 

GAAP Net Loss from continuing operations for the third quarter of 2025 was $9.9 million, compared to a net loss of $6.4 million in the second quarter of 2025 and a net loss of $15.8 million in the third quarter of 2024.

 

Adjusted EBITDA from continuing operations was $17.0 million for the third quarter of 2025, or 26.1% of revenue, compared to Adjusted EBITDA from continuing operations of $16.0 million for the second quarter of 2025, or 24.6% of revenue, and $16.9 million, or 25.9% of revenue for the third quarter of 2024.

 

Balance Sheet and Cash Flow


Cash and cash equivalents were $36.6 million as of September 30, 2025. Net cash provided by continuing operations in the third quarter of 2025 was $7.1 million, after net tax payments of $5 million during the quarter.

 

This represents the Company’s thirteenth consecutive quarter of positive cash flow from continuing operations. Capex spending was $2.2 million in the third quarter, mainly related to expansions at the Maryland and New Jersey facilities. Free cash flow was $4.9 million in the third quarter of 2025, representing the ninth consecutive quarter of positive free cash flow.

 

During the third quarter, the Company closed on an upsized senior secured syndicated term loan of $79 million, the majority of which was used to retire existing indebtedness, with the remainder designated for future growth initiatives. As part of this transaction, the Company executed an additional uncommitted term loan facility in an aggregate principal amount of up to $35 million for future M&A.

 

As of September 30, 2025, there were approximately 382 million basic shares of the Company issued and outstanding, including 307 million common shares, 11 million preferred shares as converted, and 63 million exchangeable shares. Additionally, there were 23 million warrants and options outstanding at a weighted average price of $3.71.

 

Conference Call Details

 

TerrAscend will host a conference call today, November 6, 2025, to discuss these results. Jason Wild, Executive Chairman, Ziad Ghanem, President and Chief Executive Officer, and Alisa Campbell, Interim Chief Financial Officer, will host the call starting at 8:30 a.m. Eastern time. A question-and-answer session will follow management's presentation.

 

 

 

 

Date:

Thursday, November 6, 2025

Time:

8:30 a.m. Eastern Time

Webcast:

https://app.webinar.net/6dvVkb2k4bz

Dial-in Number:

1-888-510-2154

Replay:

 

 

1-289-819-1450 or 1-888-660-6345

 

Available until 12:00 midnight Eastern Time on November 20, 2025

Replay Entry Code: 73897#

 

About TerrAscend

 

TerrAscend is a leading TSX-listed cannabis company with interests across the North American cannabis sector, including operations in Pennsylvania, New Jersey, Maryland, Ohio, and California through TerrAscend Growth Corp. and retail operations in Canada. TerrAscend operates The Apothecarium and other dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. TerrAscend’s cultivation and manufacturing practices yield consistent, high-quality cannabis, providing industry-leading product selection to both the medical and legal adult-use markets. The Company owns or licenses several synergistic businesses and brands including The Apothecarium, Cookies, Ilera Healthcare, Kind Tree, Legend, State Flower, Wana, and Valhalla Confections. For more information visit www.terrascend.com.

 

Caution Regarding Cannabis Operations in the United States
 

Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Cannabis remains a Schedule I drug under the U.S. Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis in the United States. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation.

 


While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve TerrAscend of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against TerrAscend. The enforcement of federal laws in the United States is a significant risk to the business of TerrAscend and any proceedings brought against TerrAscend thereunder may adversely affect TerrAscend’s operations and financial performance.

 

Forward-Looking Information
 

This press release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and include, but not limited to, statements with respect to the Company’s expectations with respect to its business outlook, financial profile, and operational efficiencies; its market opportunities, growth prospects in new and existing markets, and M&A strategy; the expected benefits of, and the Company’s ability to execute on, its exit plans in Michigan; and the Company’s expectation of future availability of funds under the uncommitted term loan of up to $35 million. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

 

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, current and future market conditions; risks related to federal, state, provincial, territorial, local and foreign government laws, rules and regulations, including federal and state laws in the United States relating to cannabis operations in the United States; and the risk factors set out in the Company’s most recently filed MD&A, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca and in the section titled “Risk Factors” in the Company’s Annual Report for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March 6, 2025.

 

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether, as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.

 

Definition and Reconciliation of Non-GAAP Measures

 

In addition to reporting the financial results in accordance with GAAP, the Company reports certain financial results that differ from what is reported under GAAP. Non-GAAP measures used by management do not have any standardized meaning prescribed by GAAP and may not be comparable to similar measures presented by other companies. The Company believes that certain investors and analysts use these measures to measure a company’s ability to meet other payment obligations or as a common measurement to value companies in the cannabis industry, and the Company calculates: (i) Free cash flow from net cash provided by operating activities from continuing operations less capital expenditures for property and equipment, which management believes is an important measurement of the Company's ability to generate additional cash from its business operations, and (ii) EBITDA from continuing operations and Adjusted EBITDA from continuing operations as net loss, adjusted to exclude provision for income taxes, finance expenses, depreciation and amortization, share-based compensation, loss on extinguishment of debt, (gain) loss from revaluation of contingent consideration, unrealized and realized (gain) loss on investments, unrealized and realized foreign exchange (gain) loss, loss (gain) on fair value of derivative liabilities, impairment of property and equipment and right of use assets, gain on lease termination, and certain other items, which management believes is not reflective of the ongoing operations and performance of the Company. Such information is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP.

 

For more information regarding TerrAscend:

Ziad Ghanem
Chief Executive Officer
IR@terrascend.com
689-345-4114

 

Investor Relations Contact:

KCSA Strategic Communications

Valter Pinto, Managing Director


Valter@KCSA.com

212-896-1254

 

 

 


TerrAscend Corp.

Consolidated Balance Sheets

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

 

 

At

 

 

At

 

 

 

September 30, 2025

 

 

December 31, 2024

 

Assets

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

Cash and cash equivalents

 

$

36,516

 

 

$

26,381

 

Restricted cash

 

 

110

 

 

 

606

 

Accounts receivable, net

 

 

17,116

 

 

 

20,224

 

Investments

 

 

991

 

 

 

1,727

 

Inventory

 

 

33,942

 

 

 

39,672

 

Prepaid expenses and other current assets

 

 

4,962

 

 

 

5,123

 

Assets from discontinued operations, current

 

 

25,728

 

 

 

83,155

 

Total current assets

 

 

119,365

 

 

 

176,888

 

Non-current assets

 

 

 

 

 

 

Property and equipment, net

 

 

125,633

 

 

 

124,165

 

Deposits

 

 

168

 

 

 

168

 

Operating lease right of use assets

 

 

28,253

 

 

 

28,755

 

Intangible assets, net

 

 

171,559

 

 

 

169,604

 

Goodwill

 

 

109,770

 

 

 

106,929

 

Other non-current assets

 

 

512

 

 

 

722

 

Total non-current assets

 

 

435,895

 

 

 

430,343

 

Total assets

 

$

555,260

 

 

$

607,231

 

 

 

 

 

 

 

 

Liabilities and shareholders' equity

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

$

35,993

 

 

$

40,349

 

Deferred revenue

 

 

3,885

 

 

 

3,575

 

Convertible debt, current

 

 

10,355

 

 

 

 

Loans payable

 

 

572

 

 

 

6,761

 

Contingent consideration payable

 

 

179

 

 

 

3,121

 

Operating lease liability

 

 

1,236

 

 

 

1,322

 

Derivative liability

 

 

893

 

 

 

92

 

Corporate income tax payable

 

 

8,338

 

 

 

11,531

 

Liabilities from discontinued operations

 

 

14,856

 

 

 

24,298

 

Total current liabilities

 

 

76,307

 

 

 

91,049

 

Non-current liabilities

 

 

 

 

 

 

Loans payable

 

 

211,911

 

 

 

183,461

 

Operating lease liability

 

 

30,542

 

 

 

30,664

 

Derivative liability

 

 

 

 

 

451

 

Convertible debt, non-current

 

 

 

 

 

9,114

 

Deferred income tax liability

 

 

8,720

 

 

 

8,428

 

Contingent consideration payable

 

 

 

 

 

172

 

Liability on uncertain tax position

 

 

132,213

 

 

 

106,991

 

Other long term liabilities

 

 

86

 

 

 

85

 

Total non-current liabilities

 

 

383,472

 

 

 

339,366

 

Total liabilities

 

 

459,779

 

 

 

430,415

 

Commitments and contingencies

 

 

 

 

 

 

Shareholders' equity

 

 

 

 

 

 

Share capital

 

 

 

 

 

 

Series A, convertible preferred stock, no par value, unlimited shares authorized; 10,850 and 12,350 shares outstanding as of September 30, 2025 and December 31, 2024, respectively

 

 

 

 

 

 

Series B, convertible preferred stock, no par value, unlimited shares authorized; 600 and 600 shares outstanding as of September 30, 2025 and December 31, 2024, respectively

 

 

 

 

 

 

Exchangeable shares, no par value, unlimited shares authorized; 63,492,038 and 63,492,038 shares outstanding as of September 30, 2025 and December 31, 2024, respectively

 

 

 

 

 

 

Common shares, no par value, unlimited shares authorized; 306,967,397 and 293,232,131 shares outstanding as of September 30, 2025 and December 31, 2024, respectively

 

 

 

 

 

 

Treasury stock, no par value; nil and 129,500 shares outstanding as of September 30, 2025 and December 31, 2024, respectively

 

 

 

 

 

 

Additional paid in capital

 

 

958,927

 

 

 

952,463

 

Accumulated other comprehensive income

 

 

2,168

 

 

 

3,011

 

Accumulated deficit

 

 

(867,229

)

 

 

(778,514

)

Non-controlling interest

 

 

1,615

 

 

 

(144

)

Total shareholders' equity

 

 

95,481

 

 

 

176,816

 

Total liabilities and shareholders' equity

 

$

555,260

 

 

$

607,231

 

 


TerrAscend Corp.

Consolidated Statements of Operations and Comprehensive Loss

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

 

 

 

 

For the Three Months Ended

 

 

For the Nine Months Ended

 

 

 

 

September 30, 2025

 

 

September 30, 2024

 

 

 

September 30, 2025

 

 

September 30, 2024

 

Revenue, net

 

 

$

65,101

 

 

$

65,161

 

 

 

$

194,410

 

 

$

201,632

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of sales

 

 

 

31,176

 

 

 

31,950

 

 

 

 

92,568

 

 

 

100,892

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

 

33,925

 

 

 

33,211

 

 

 

 

101,842

 

 

 

100,740

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

 

21,327

 

 

 

24,717

 

 

 

 

63,456

 

 

 

68,426

 

Amortization and depreciation

 

 

 

1,457

 

 

 

1,240

 

 

 

 

4,030

 

 

 

3,793

 

Impairment of property and equipment and right of use assets

 

 

 

 

 

 

 

 

 

 

 

 

 

2,438

 

Other operating income

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,169

)

Total operating expenses

 

 

 

22,784

 

 

 

25,957

 

 

 

 

67,486

 

 

 

73,488

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income from operations

 

 

 

11,141

 

 

 

7,254

 

 

 

 

34,356

 

 

 

27,252

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other expense (income)

 

 

 

 

 

 

 

 

 

 

 

 

Finance and other expenses

 

 

 

8,952

 

 

 

8,291

 

 

 

 

26,034

 

 

 

25,094

 

Unrealized and realized loss (gain) on investments

 

 

 

1

 

 

 

(14

)

 

 

 

736

 

 

 

213

 

(Gain) loss from revaluation of contingent consideration

 

 

 

(1,171

)

 

 

327

 

 

 

 

(825

)

 

 

3,547

 

Loss on extinguishment of debt

 

 

 

1,432

 

 

 

2,096

 

 

 

 

1,432

 

 

 

2,096

 

Loss (gain) on fair value of derivative liabilities

 

 

 

723

 

 

 

(669

)

 

 

 

347

 

 

 

(2,608

)

Unrealized and realized foreign exchange loss (gain)

 

 

 

77

 

 

 

(214

)

 

 

 

(530

)

 

 

175

 

Income (loss) from continuing operations before provision for income taxes

 

 

 

1,127

 

 

 

(2,563

)

 

 

 

7,162

 

 

 

(1,265

)

Provision for income taxes

 

 

 

11,034

 

 

 

13,273

 

 

 

 

31,139

 

 

 

30,052

 

Net loss from continuing operations

 

 

$

(9,907

)

 

$

(15,836

)

 

 

$

(23,977

)

 

$

(31,317

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Discontinued operations:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from discontinued operations, net of tax

 

 

$

(14,647

)

 

$

(5,583

)

 

 

$

(60,952

)

 

$

(11,191

)

Net loss

 

 

$

(24,554

)

 

$

(21,419

)

 

 

$

(84,929

)

 

$

(42,508

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustment

 

 

 

3

 

 

 

1,872

 

 

 

 

843

 

 

 

1,214

 

Comprehensive loss

 

 

$

(24,557

)

 

$

(23,291

)

 

 

$

(85,772

)

 

$

(43,722

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss from continuing operations attributable to:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common and proportionate Shareholders of the Company

 

 

$

(11,112

)

 

$

(17,565

)

 

 

$

(27,762

)

 

$

(37,193

)

Non-controlling interests

 

 

$

1,205

 

 

$

1,729

 

 

 

 

3,785

 

 

$

5,876

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive loss attributable to:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common and proportionate Shareholders of the Company

 

 

$

(25,762

)

 

$

(25,020

)

 

 

$

(89,557

)

 

$

(49,598

)

Non-controlling interests

 

 

$

1,205

 

 

$

1,729

 

 

 

 

3,785

 

 

$

5,876

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share - basic & diluted:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

 

$

(0.04

)

 

$

(0.06

)

 

 

$

(0.09

)

 

$

(0.13

)

Discontinued operations

 

 

 

(0.05

)

 

 

(0.02

)

 

 

 

(0.20

)

 

 

(0.04

)

Net loss per share - basic & diluted (1)

 

 

$

(0.08

)

 

$

(0.08

)

 

 

$

(0.30

)

 

$

(0.17

)

Weighted average number of outstanding common shares - basic & diluted

 

 

 

306,302,270

 

 

 

291,647,146

 

 

 

 

299,550,448

 

 

 

291,252,902

 

 

 


TerrAscend Corp.

Consolidated Statements of Cash Flows

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

 

For the Nine Months Ended

 

 

September 30, 2025

 

 

September 30, 2024

 

Operating activities

 

 

 

 

 

Net loss from continuing operations

$

(23,977

)

 

$

(31,317

)

Adjustments to reconcile net loss to net cash provided by operating activities

 

 

 

 

 

Accretion expense

 

6,128

 

 

 

8,448

 

Depreciation of property and equipment and amortization of intangible assets

 

11,663

 

 

 

11,357

 

Amortization of operating right-of-use assets

 

1,208

 

 

 

1,163

 

Share-based compensation

 

3,659

 

 

 

7,720

 

Deferred income tax expense (benefit)

 

291

 

 

 

(986

)

Loss (gain) on fair value of derivative liabilities

 

347

 

 

 

(2,608

)

Unrealized and realized loss on investments

 

736

 

 

 

213

 

(Gain) loss from revaluation of contingent consideration

 

(825

)

 

 

3,547

 

Provision for expected credit loss (recovery)

 

988

 

 

 

(1,136

)

Loss on extinguishment of debt

 

1,432

 

 

 

2,096

 

Unrealized and realized foreign exchange (gain) loss

 

(530

)

 

 

175

 

Impairment and other

 

(5

)

 

 

1,270

 

Changes in operating assets and liabilities

 

 

 

 

 

Receivables

 

2,084

 

 

 

671

 

Inventory

 

6,056

 

 

 

1,005

 

Accounts payable and accrued liabilities

 

(5,336

)

 

 

(3,187

)

Income taxes payable and tax related liabilities

 

22,027

 

 

 

42,998

 

Prepaid expense and other current assets

 

49

 

 

 

(1,129

)

Other assets and liabilities

 

(396

)

 

 

(876

)

Net cash provided by operating activities - continuing operations

 

25,599

 

 

 

39,424

 

Net cash used in operating activities - discontinued operations

 

(12,085

)

 

 

(11,222

)

Net cash provided by operating activities

 

13,514

 

 

 

28,202

 

 

 

 

 

 

 

Investing activities

 

 

 

 

 

Investment in property and equipment

 

(6,898

)

 

 

(4,111

)

Investment in note receivable, net of interest received

 

165

 

 

 

(1,523

)

Investment in intangible assets

 

(726

)

 

 

(115

)

Cash portion of consideration paid in acquisitions, net of cash acquired

 

(5,128

)

 

 

(250

)

Net cash used in investing activities - continuing operations

 

(12,587

)

 

 

(5,999

)

Net cash used in investing activities - discontinued operations

 

(877

)

 

 

(270

)

Net cash used in investing activities

 

(13,464

)

 

 

(6,269

)

 

 

 

 

 

 

Financing activities

 

 

 

 

 

Proceeds from loan payable, net of transaction costs

 

78,944

 

 

 

129,382

 

Loan principal paid

 

(65,898

)

 

 

(136,290

)

Capital distributions paid to non-controlling interests

 

(2,046

)

 

 

(4,433

)

Payment for contingent consideration

 

(386

)

 

 

 

Payments made for financing obligations and finance lease

 

 

 

 

(271

)

Loan exit fee paid

 

(233

)

 

 

(500

)

Repurchases of common shares

 

(377

)

 

 

(138

)

Net cash provided by (used in) financing activities- continuing operations

 

10,004

 

 

 

(12,250

)

Net cash used in financing activities- discontinued operations

 

 

 

 

(8,066

)

Net cash provided by (used in) financing activities

 

10,004

 

 

 

(20,316

)

 

 

 

 

 

 

Net increase in cash and cash equivalents and restricted cash during the period

 

10,054

 

 

 

1,617

 

Net effects of foreign exchange

 

(415

)

 

 

278

 

Cash and cash equivalents and restricted cash, beginning of the period

 

26,987

 

 

 

25,347

 

Cash and cash equivalents and restricted cash, end of the period

$

36,626

 

 

$

27,242

 

 


 

TerrAscend Corp.

Reconciliation of GAAP to Non-GAAP Financial Measures

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

 

The table below reconciles net loss to EBITDA and Adjusted EBITDA:

 

 

 

For the Three Months Ended

 

 

 

September 30, 2025

 

 

June 30, 2025

 

 

September 30, 2024

 

Net loss

 

 

(24,554

)

 

 

(48,107

)

 

 

(21,419

)

Loss from discontinued operations

 

 

14,647

 

 

 

41,701

 

 

 

5,583

 

Loss from continued operations

 

 

(9,907

)

 

 

(6,406

)

 

 

(15,836

)

 

 

 

 

 

 

 

 

 

 

Add (deduct) the impact of:

 

 

 

 

 

 

 

 

 

Provision for income taxes

 

 

11,034

 

 

 

9,598

 

 

 

13,273

 

Finance expenses

 

 

9,243

 

 

 

8,962

 

 

 

8,514

 

Amortization and depreciation

 

 

3,934

 

 

 

3,784

 

 

 

3,781

 

EBITDA

 

 

14,304

 

 

 

15,938

 

 

 

9,732

 

Add (deduct) the impact of:

 

 

 

 

 

 

 

 

 

Share-based compensation

 

 

1,366

 

 

 

779

 

 

 

4,275

 

Loss on extinguishment of debt

 

 

1,432

 

 

 

 

 

 

2,096

 

Loss (gain) on fair value of derivative liabilities

 

 

723

 

 

 

(279

)

 

 

(669

)

Unrealized and realized foreign exchange loss (gain)

 

 

77

 

 

 

(648

)

 

 

(214

)

Unrealized and realized loss (gain) on investments

 

 

1

 

 

 

(7

)

 

 

(14

)

(Gain) loss from revaluation of contingent consideration

 

 

(1,171

)

 

 

(34

)

 

 

327

 

Other one-time items

 

 

266

 

 

 

267

 

 

 

1,351

 

Adjusted EBITDA

 

$

16,998

 

 

$

16,016

 

 

$

16,884

 

Adjusted EBITDA Margin

 

 

26.1

%

 

 

24.6

%

 

 

25.9

%

 

 

The table below reconciles Net cash provided by operating activities to Free Cash Flow:

 

 

 

For the Three Months Ended

 

 

 

September 30, 2025

 

 

June 30, 2025

 

 

September 30, 2024

 

Net cash provided by operating activities - continuing operations

 

$

7,120

 

 

$

7,300

 

 

$

6,107

 

Capital expenditures for property and equipment

 

 

(2,248

)

 

 

(2,292

)

 

 

(17

)

Free Cash Flow

 

$

4,872

 

 

$

5,008

 

 

$

6,090